Surrogate endpoints in clinical trials: when is good...good enough?

Hepatobiliary Surg Nutr. 2024 Dec 1;13(6):1062-1064. doi: 10.21037/hbsn-24-607. Epub 2024 Nov 21.

Authors

Jamie Olapo Schnuck^{1

2}, Sardar Shahmir B Chauhan^{1

2}, Jonathan G Sham^{1

2}

Affiliations

¹ Department of Surgery, University of Washington, Seattle, WA, USA.
² Fred Hutchinson Cancer Center, Seattle, WA, USA.

No abstract available

Keywords: Overall survival (OS); clinical trials; hepato-biliary-pancreatic malignancies; recurrence-free survival (RFS); surrogate endpoints.

Publication types

Editorial
Comment